Trial Profile
A Phase II study to evaluate the safety and efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Terguride (Primary)
- Indications Fibrosis; Systemic scleroderma
- Focus Biomarker; Proof of concept; Therapeutic Use
- 31 Jan 2017 New trial record